These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36178088)

  • 1. Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.
    Sindone A; Doehner W; Comin-Colet J
    ESC Heart Fail; 2023 Feb; 10(1):44-56. PubMed ID: 36178088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Benson L; Fudim M; Corovic Cabrera C; Dahlström U; Rosano GMC; Jankowska EA; Anker SD; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Nov; 23(11):1844-1854. PubMed ID: 34476878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
    Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
    Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
    Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
    Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A; Ojeda López R; Portolés Pérez JM;
    Nefrologia; 2017; 37(6):587-591. PubMed ID: 28610806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study.
    Wahid M; Islam S; Sepehrvand N; Dover DC; McAlister FA; Kaul P; Ezekowitz JA
    Circ Heart Fail; 2024 Apr; 17(4):e011351. PubMed ID: 38572652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
    Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: A network meta-analysis of randomized controlled trials.
    Mei Z; Chen J; Luo S; Jin L; Liu Q; Chen Y
    Pharmacol Res; 2022 Aug; 182():106345. PubMed ID: 35810949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron for acute and chronic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency: An updated systematic review and meta-analysis.
    Awad AK; Abdelgalil MS; Gonnah AR; Mouffokes A; Ahmad U; Awad AK; Elbadawy MA; Roberts DH
    Clin Med (Lond); 2024 May; 24(3):100211. PubMed ID: 38643833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
    Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency.
    Borreda I; Zukermann R; Epstein D; Marcusohn E
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211055639. PubMed ID: 34994220
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
    Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
    Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
    McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA
    Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.